Immatics N.V.

Immatics N.V. presented updated clinical trial data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapy at the 2026 ESMO Annual Meeting. IMA402 demonstrated encouraging anti-tumor activity and a favorable safety profile, with a 32% cORR in PRAME-high melanoma patients. IMA203CD8 showed deep and durable anti-tumor activity across multiple tumor types, with a 55% cORR in heavily pretreated gynecologic cancer patients. The company also provided an update on anzu-cel (IMA203), which is progressing in its Phase 3 SUPRAME trial.

Immatics N.V. announced it will present three clinical data updates at the European Society for Medical Oncology (ESMO) Congress 2026. The presentations will include Phase 1b data for anzu-cel in metastatic cutaneous and uveal melanoma, Phase 1 data for IMA203CD8 across various PRAME-positive solid tumors, and Phase 1b data for IMA402 at its recommended Phase 2 dose range. These updates underscore the broad applicability and continued development of Immatics' PRAME franchise across cell therapies and bispecifics.

Immatics N.V. held its Annual General Meeting of Shareholders (AGM) on June 18, 2026, where all voting items on the agenda were approved. Key approvals included the adoption of the 2025 annual accounts, discharge of liability for board members, and the reappointment of several directors. Shareholders also extended the Board's authorization to acquire shares and approved the 2026 stock option and incentive plan.

Immatics N.V. announced its Annual General Meeting (AGM) will be held on June 18, 2026, at 16:00 CEST in Amsterdam. The record date for shareholders to vote is May 21, 2026. The agenda includes the adoption of the 2025 statutory annual accounts, discharge of board members, and the reappointment of three directors. Key proposals also include extending the Board's authorization to acquire ordinary shares and approving the 2026 Stock Option and Incentive Plan, which reserves 6,448,836 shares.

Immatics N.V. presented updated Phase 1/1b clinical data for three PRAME-targeting therapies (IMA203CD8, IMA401, and anzu-cel) at the 2026 ASCO Annual Meeting, demonstrating significant anti-tumor activity and manageable tolerability across various hard-to-treat solid tumors. IMA203CD8 showed a 63% ORR in gynecologic cancers and 67% ORR in synovial sarcoma. IMA401 achieved a 29% cORR in head and neck cancer and is advancing into a combination trial with IMA402 in lung cancer. Anzu-cel reported a 56% cORR in metastatic melanoma with durable responses, keeping its Phase 3 SUPRAME trial on track for BLA submission in 1H 2027.

Immatics N.V. announced extended positive data from its Phase 1b clinical trial of anzu-cel (IMA203) PRAME TCR T-cell therapy for advanced melanoma. The one-time infusion demonstrated rapid, deep, and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanoma. Anzu-cel achieved a 56% confirmed Overall Response Rate (ORR), 14.6 months median Duration of Response (mDOR), 6.1 months median Progression-Free Survival (mPFS), and 16.2 months median Overall Survival (mOS) with a manageable tolerability profile. These findings reinforce the drug's effectiveness, keeping the Phase 3 SUPRAME trial on track for a Biologics License Application (BLA) submission in 1H 2027.

Immatics N.V. announced extended positive Phase 1 clinical trial data for its TCR bispecific candidate IMA401 targeting MAGEA4/8 in heavily pretreated solid tumor patients. The data, presented at ASCO and published in Nature Medicine, showed deep and durable responses in various indications, including a 29% confirmed ORR and 8.8 months mDOR in head and neck cancer, alongside a favorable tolerability profile. Building on these results, Immatics has initiated enrollment for a Phase 1 combination cohort evaluating IMA401 with IMA402 (PRAME bispecific) in squamous cell non-small cell lung cancer, with initial data anticipated in 2027.

Immatics N.V. announced updated positive Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at ASCO 2026. The therapy demonstrated significant anti-tumor activity, with a 63% objective response rate (ORR) and 50% confirmed ORR (cORR) in platinum-resistant ovarian and uterine cancer, including four complete responses. In synovial sarcoma, IMA203CD8 achieved a 67% ORR and 64% cORR, with responses lasting up to approximately three years. The treatment exhibited a manageable and consistent tolerability profile across all patient populations, supporting its continued development in PRAME-positive solid tumors.

Immatics N.V. reported a net loss of 57.8 million for Q1 2026, an increase from 39.9 million in Q1 2025, primarily due to higher R&D expenses and lower collaboration revenue. Despite the financial loss, the company highlighted significant clinical progress, including the expected interim and final analysis for its lead PRAME cell therapy, anzu-cel, in 2026, and multiple other clinical data readouts across its portfolio. Immatics maintains a strong financial position with $521.5 million in cash and financial assets, projecting a cash runway into 2028.

Immatics N.V. announced that all four of its submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will cover updated clinical data for its PRAME cell therapies, including anzu-cel and IMA203CD8, across various cancers like melanoma, gynecologic cancers, and synovial sarcoma. Additionally, first-in-human results for the MAGEA4/8 bispecific, IMA401, will be presented, underscoring the continued advancement of Immatics' PRAME franchise in developing novel immunotherapies for solid tumors.